These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 39182110

  • 1. The fentanyl made me feel like I needed more methadone": changes in the role and use of medication for opioid use disorder (MOUD) due to fentanyl.
    Bolshakova M, Simpson KA, Ganesh SS, Goldshear JL, Page CJ, Bluthenthal RN.
    Harm Reduct J; 2024 Aug 24; 21(1):156. PubMed ID: 39182110
    [Abstract] [Full Text] [Related]

  • 2. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW, Tapper A, Rapisarda SS, Stopka TJ, Palacios WR, Case P, Silcox J, Moyo P, Green TC.
    Subst Abuse Treat Prev Policy; 2023 May 22; 18(1):30. PubMed ID: 37217975
    [Abstract] [Full Text] [Related]

  • 3. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME, Wood E, Le Foll B, Lim R, Choi JC, Mok WY, Bruneau J, Rehm J, Wild TC, Bozinoff N, Hassan A, Jutras-Aswad D, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse.
    Addiction; 2022 Oct 22; 117(10):2662-2672. PubMed ID: 35712892
    [Abstract] [Full Text] [Related]

  • 4. Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.
    Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD.
    Addiction; 2023 Aug 22; 118(8):1549-1556. PubMed ID: 37158468
    [Abstract] [Full Text] [Related]

  • 5. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
    Dickson-Gomez J, Krechel S, Ohlrich J, Montaque HDG, Weeks M, Li J, Havens J, Spector A.
    Harm Reduct J; 2024 Feb 27; 21(1):52. PubMed ID: 38413972
    [Abstract] [Full Text] [Related]

  • 6. The Lived Experiences of Pregnant and Parenting Women in Recovery Toward Medication Treatment for Opioid Use Disorder.
    Titus-Glover D, Shaya FT, Welsh C, Roane L.
    Subst Use Addctn J; 2024 Jul 27; 45(3):367-377. PubMed ID: 38254261
    [Abstract] [Full Text] [Related]

  • 7. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N, Adnan T, Peréa F, Baggett TP, Chatterjee A.
    J Subst Abuse Treat; 2022 Jul 27; 138():108752. PubMed ID: 35277306
    [Abstract] [Full Text] [Related]

  • 8. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B, El Shahawy O, Segoshi A, Moreno KP, Badiei B, Sarker A, Krawczyk N.
    J Addict Dis; 2021 Jul 27; 39(1):37-45. PubMed ID: 32835641
    [Abstract] [Full Text] [Related]

  • 9. "It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply.
    Shin SS, LaForge K, Stack E, Pope J, Leichtling G, Larsen JE, Leahy JM, Seaman A, Hoover D, Chisholm L, Blazes C, Baker R, Byers M, Branson K, Korthuis PT.
    Harm Reduct J; 2022 Jul 11; 19(1):76. PubMed ID: 35818072
    [Abstract] [Full Text] [Related]

  • 10. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N, Kennedy AJ, Taubenberger S, Chang JC, Hacker K.
    Subst Abus; 2022 Jul 11; 43(1):742-748. PubMed ID: 35100094
    [Abstract] [Full Text] [Related]

  • 11. Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study.
    Smolina K, Crabtree A, Chong M, Park M, Mill C, Zhao B, Schütz CG.
    Subst Abus; 2022 Jul 11; 43(1):92-98. PubMed ID: 32441588
    [Abstract] [Full Text] [Related]

  • 12. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study.
    Carroll JJ, Marshall BDL, Rich JD, Green TC.
    Int J Drug Policy; 2017 Aug 11; 46():136-145. PubMed ID: 28578864
    [Abstract] [Full Text] [Related]

  • 13. Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.
    Socias ME, Wood E, Dong H, Brar R, Bach P, Murphy SM, Fairbairn N.
    Contemp Clin Trials; 2020 Apr 11; 91():105993. PubMed ID: 32194251
    [Abstract] [Full Text] [Related]

  • 14. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S, Nobel I, Allen LR, Richardson LD, Vidal K, Manini AF.
    Am J Emerg Med; 2022 Jan 11; 51():114-118. PubMed ID: 34735968
    [Abstract] [Full Text] [Related]

  • 15. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.
    JAMA Netw Open; 2020 Feb 05; 3(2):e1920622. PubMed ID: 32022884
    [Abstract] [Full Text] [Related]

  • 16. Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyls, drug discernment, and the radical transformation of the illicit opioid market.
    Duhart Clarke SE, Kral AH, Zibbell JE.
    Int J Drug Policy; 2022 Jan 05; 99():103467. PubMed ID: 34662847
    [Abstract] [Full Text] [Related]

  • 17. Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.
    Erath TG, LaCroix R, O'Keefe E, Higgins ST, Rawson RA.
    Harm Reduct J; 2024 Apr 05; 21(1):76. PubMed ID: 38580997
    [Abstract] [Full Text] [Related]

  • 18. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
    Frost MC, Austin EJ, Corcorran MA, Briggs ES, Behrends CN, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Des Jarlais DC, Williams EC, Glick SN.
    Harm Reduct J; 2022 Jul 19; 19(1):79. PubMed ID: 35854351
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA.
    Addict Sci Clin Pract; 2022 Mar 07; 17(1):15. PubMed ID: 35255967
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S, Sun L, Vakkalanka JP.
    Am J Emerg Med; 2024 Aug 07; 82():52-56. PubMed ID: 38795424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.